These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38696157)

  • 1. [Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study].
    Ponomareva EV; Androsova LV; Krinsky SA; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4. Vyp. 2):92-99. PubMed ID: 38696157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment].
    Kolykhalov IV; Androsova LV; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):59-66. PubMed ID: 36412158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment].
    Gavrilova SI; Kolykhalov IV; Ponomareva EV; Fedorova YB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(5):45-53. PubMed ID: 29927403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].
    Selezneva ND; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):90-97. PubMed ID: 37655416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Citicoline in the treatment of cognitive impairment in first-degree relatives of AD patients: the influence of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Roshchina IF; Ponomareva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):30-36. PubMed ID: 34870911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion pattern and predictive factor of mild cognitive impairment in elderly Koreans.
    Shim SM; Song J; Kim JH; Jeon JP
    Arch Gerontol Geriatr; 2016; 64():146-50. PubMed ID: 26896864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment.
    Lee SH; Choi BY; Kim JH; Kho AR; Sohn M; Song HK; Choi HC; Suh SW
    Brain Res; 2017 Jan; 1654(Pt A):66-76. PubMed ID: 27765578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers].
    Alesenko AV; Gavrilova SI; Gutner UA; Lebedeva AO; Shupik MA; Kolykhalov IV; Ponomareva EV; Selezneva ND; Fedorova YB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):21-27. PubMed ID: 28745666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial.
    Shin HY; Kim HR; Jahng GH; Jin C; Kwon S; Cho SY; Park SU; Jung WS; Moon SK; Ko CN; Park JM
    BMC Complement Med Ther; 2021 Oct; 21(1):251. PubMed ID: 34620151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction Model of Conversion to Dementia Risk in Subjects with Amnestic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study.
    Jang H; Ye BS; Woo S; Kim SW; Chin J; Choi SH; Jeong JH; Yoon SJ; Yoon B; Park KW; Hong YJ; Kim HJ; Lockhart SN; Na DL; Seo SW
    J Alzheimers Dis; 2017; 60(4):1579-1587. PubMed ID: 28968237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial.
    Carotenuto A; Andreone V; Amenta F; Traini E
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929542
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prognosis of amnestic mild cognitive impairment: clinical and immunological correlations].
    Ponomareva EV; Krinsky SA; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):16-22. PubMed ID: 34870909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment].
    Gavrilova SI; Volpina OM; Kolykhalov IV; Fedorova YB; Selezneva ND; Ponomareva EV; Koroev DO; Kamynina AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):27-38. PubMed ID: 28884714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment.
    Jung YH; Park S; Jang H; Cho SH; Kim SJ; Kim JP; Kim ST; Na DL; Seo SW; Kim HJ
    Sci Rep; 2020 Jan; 10(1):772. PubMed ID: 31964931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of memory impairment as a prognostic marker in amnestic mild cognitive impairment.
    Lee M; Lim TS; Lee HY; Moon SY
    J Neurol Sci; 2014 Dec; 347(1-2):124-8. PubMed ID: 25394906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia.
    Roberts RO; Christianson TJ; Kremers WK; Mielke MM; Machulda MM; Vassilaki M; Alhurani RE; Geda YE; Knopman DS; Petersen RC
    JAMA Neurol; 2016 Jan; 73(1):93-101. PubMed ID: 26569387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study.
    Xie B; Liu Z; Jiang L; Liu W; Song M; Zhang Q; Zhang R; Cui D; Wang X; Xu S
    J Alzheimers Dis; 2017; 55(2):509-520. PubMed ID: 27662297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.
    Chung JK; Plitman E; Nakajima S; Chakravarty MM; Caravaggio F; Takeuchi H; Gerretsen P; Iwata Y; Patel R; Mulsant BH; Graff-Guerrero A
    J Alzheimers Dis; 2016; 49(3):743-54. PubMed ID: 26519442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.